US Patent Issued to Nammi Therapeutics on May 27 for "Formulated and/or co-formulated liposome compositions containing toll-like receptor("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof" (California, New York Inventors)

ALEXANDRIA, Va., June 17 -- United States Patent no. 12,311,010, issued on May 27, was assigned to Nammi Therapeutics Inc. (Los Angeles).

"Formulated and/or co-formulated liposome compositions containing toll-like receptor("TLR") agonist prodrugs useful in the treatment of cancer and methods thereof" was invented by David Stover (Los Angeles), Dhruba Bharali (Sherman Oaks, Calif.), Bruce A Hay (Niskayuna, N.Y.) and Tahmineh Safaie (Yucca Valley, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid mo...